Business Wire

PA-BOOMI

Share
Boomi Research Reveals Composability Essential to Overcome Legacy System Challenges in Enterprises

Boomi™, the intelligent integration and automation leader, today announced findings of a new global study.1 The IDC InfoBrief, sponsored by IFS and Boomi, reveals that aging, monolithic systems, and a lack of technological understanding at the executive level limit organizational agility and responsiveness to disruptions. The research also identified that having a composable strategy is key for organizations to overcome these challenges.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613200694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Research Reveals Composability Essential to Overcome Legacy System Challenges in Enterprises (Graphic: Business Wire)

The study polled over 1,000 C-level respondents across 12 countries in Europe, North America, Middle East, Africa, and Asia Pacific. It found that legacy technology platforms and unfamiliarity with the essential role Application Programming Interfaces (APIs) and composability play in unlocking business data are combining to hamper insights and transformation.

The widely acknowledged risks of not transitioning to composable applications have become even more pressing against the backdrop of current domestic and international upheavals. Recent developments such as Brexit, world issues, and the escalating cost-of-living crises have highlighted the deficiencies of outdated technologies.

While most businesses believe they have withstood the last three years of disruption, leaders report that working capital and inventory imbalances (56%), volatile demand (53%), and unpredictable supply chains (48%) had been their biggest challenges. Respondents also pointed to legacy applications (60%), lack of integration (48%), and inflexible/monolithic applications (43%) as hindering efforts to overcome these challenges - impacting the efficiency with which they can mitigate risks.

The research also revealed that the consequences of outdated technology platforms are being felt by businesses, with reports of limited visibility into operational processes (24%) and poor internal collaboration (18%). These findings suggest that companies struggle to use their data in long-term planning, hampering business agility and the ability to respond to future disruptions effectively.

With more than two-fifths (41%) of organizations lacking a composable strategy, the risk of stagnation and mounting technical debt is glaring. While the value of a composable architecture is well understood by over 70% of the C-suite respondents with business and functional responsibilities, the Board level professionals lag in their understanding - only 19% are clear on the value composability creates. This gulf between senior level executives points to a need for education and clearer business cases that highlight composability’s short, medium, and long-term value.

“This research sends a clear message to executives: To remain competitive, increase agility, and drive productivity across their entire business, composability is key,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “Speed to realizing value requires a strong data foundation and a mature cloud strategy as prerequisites to the adoption of other advanced technologies.”

Encouragingly, 89% of respondents identified API-driven innovation as a key component of composability with over half (51%) pointing to seamless integration between process workflows, and 37% to the importance of single-platform solutions. As well as highlighting the essential role of APIs in creating adaptable and flexible business systems, these findings support the notion that the future of business applications is composable.

In terms of technology preferences, APIs lead the way with 82% of respondents emphasizing their significance, followed by Artificial Intelligence (45%) and Machine Learning (40%). The research indicated that supply chain (51%), procurement (47%), and customer service and support (40%) are the top areas organizations believe they would benefit from application composability.

Despite the recognized importance of composability, the challenges identified in the research highlight the need for broader organizational alignment and clarity in technological direction to fully leverage the advantages of a composable architecture, where APIs play a foundational role.

Nevertheless, the survey data does reveal a significant trend towards investing in composing workflows with multiple products using APIs. Twenty-two percent of respondents reported to be actively pursuing this approach, reflecting a strategic move towards leveraging APIs for integrating diverse systems and applications to drive efficiency and innovation, and eliminate waste.

Macosky concluded: “Inertia in moving to the cloud or formulating a clear composability strategy is likely to prevent businesses from unlocking the full value of AI and machine learning technology. The challenge for organizations now is to realize value pervasively. However, they must overcome considerable barriers, such as the lack of understanding of composability’s value at the executive level and inadequate progression within cloud journeys. It should therefore come as little surprise that the CIO and CTO are the primary champions for composability.”

Additional Resources

  • Download the IDC InfoBrief, sponsored by IFS and Boomi, a Global Study of Composability in Enterprise Software and Evolving Business Needs.
  • Watch this webinar that explores the findings of the study with guest speakers from IDC, Boomi, and IFS.

About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

____________________________
1 IDC InfoBrief, sponsored by IFS and Boomi, Global Study of Composability in Enterprise Software and Evolving Business Needs, doc #US51992524, April 2024. In December 2023, over 1,000 senior business decision makers across 12 countries were polled from the manufacturing, energy and utilities, aerospace and defense, construction and engineering, telecoms, and service industries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613200694/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye